1. Features of anaplastic lymphoma kinase rearrangement in early-stage lung cancer: Analysis of a nationwide Japanese database.
- Author
-
Matsuura Y, Mun M, Shintani Y, Okami J, Ito H, Ohtsuka T, Mori T, Watanabe SI, Chida M, Endo S, Nakanishi R, Kadokura M, Suzuki H, Miyaoka E, Yoshino I, and Date H
- Subjects
- Humans, Anaplastic Lymphoma Kinase genetics, Receptor Protein-Tyrosine Kinases genetics, Retrospective Studies, East Asian People, ErbB Receptors genetics, Mutation, Gene Rearrangement, Protein Kinase Inhibitors therapeutic use, Adenocarcinoma genetics, Adenocarcinoma surgery, Adenocarcinoma pathology, Lung Neoplasms genetics, Lung Neoplasms surgery, Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung surgery
- Abstract
Background and Objectives: Anaplastic lymphoma kinase (ALK) rearrangement is a representative driver mutation in lung cancer. However, the biology of early-stage ALK-rearranged lung cancer remains unclear. We aimed to assess the clinicopathological features, prognostic implications, and influence of ALK rearrangement on the postoperative course in surgically resected lung cancer., Methods: We retrospectively analyzed data from the Japanese Joint Committee of Lung Cancer Registry database. Of the 12 730 patients with lung adenocarcinoma, 794 (6.2%) were tested for ALK rearrangement and were included., Results: ALK rearrangements were detected in 76 patients (10%). The 5-year overall survival (OS) rate was significantly higher in the ALK rearrangement-positive group than in the ALK rearrangement-negative group (p = 0.030). Multivariable analysis revealed that ALK rearrangement was an independent prognostic factor for improved OS (hazard ratio, 0.521; 95% confidence interval, 0.298-0.911; p = 0.022). Regarding the postrecurrence state, there was no difference in the initial recurrence sites between both groups. Administration of ALK-tyrosine kinase inhibitors (TKIs) improved postrecurrence survival in any treatment lines., Conclusion: In one of the largest national surveys, ALK rearrangement was associated with improved long-term outcomes in surgically resected patients. ALK-TKIs may be an important treatment strategy for ALK rearrangement-positive lung adenocarcinoma in the postrecurrence state., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF